Onartuzumab
Information
- Drug Name
- Onartuzumab
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| gastric adenocarcinoma |
MET AMPLIFICATION ( ENST00000318493.11 ) MET AMPLIFICATION ( ENST00000318493.11 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22389872 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A case-study describing a patient with MET polysom... | MET |
MET AMPLIFICATION ( ENST00000318493.11 ) MET AMPLIFICATION ( ENST00000318493.11 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02488330 | Completed | Phase 3 | An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | August 27, 2015 | June 29, 2018 |
| NCT01519804 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | April 2012 | September 2015 |
| NCT01632228 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | June 29, 2012 | January 21, 2016 |
| NCT01662869 | Completed | Phase 3 | A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | November 2012 | December 2015 |
| NCT01887886 | Completed | Phase 3 | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation | December 2013 | February 2015 |
| NCT01897038 | Completed | Phase 1 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | September 2013 | March 2015 |
| NCT01186991 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer | March 2011 | March 2016 |
| NCT02044601 | Withdrawn | Phase 1/Phase 2 | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | June 2014 | |
| NCT01974258 | Withdrawn | Phase 1 | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | February 2014 | July 2014 |